10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Protected from light,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Piromelatine (Neu-P11) is a melatonin MT 1 /MT 2 receptor agonist, serotonin 5-HT 1A / 5-HT 1D agonist, and serotonin 5-HT 2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities
In Vivo
Piromelatine (20 mg/kg, ip, daily) treatment prevents insulin resistance induced by sleep restriction . Piromelatine (5-50 mg/kg, ip, daily) decreases plasma glucose significantly. Piromelatine (100 mg/kg) decreases thermal hyperalgesia and mechanical allodynia in PSL (partial sciatic nerve ligation) mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Twenty four male Sprague-Dawley rats (3 months old, weighing 250-300 g) . Dosage: 20 mg/kg. Administration: IP, daily at 8:00 p.m. Result: Resulted in significantly decreased plasma glucose levels (6.670.35 mmol/L, 6.770.34 mmol/L vs. 8.27 0.38 mmol/L), and the plasma glucose levels of the two groups were even neared to that of the normal control group (6.07±0.35 mmol/L). Resulted in a decrease in triglycerides and total cholesterol levels (51.8% and\n43.0%, respectively) and an elevation in HDL-C level (increase of 32.4%). Animal Model: Five groups of 12-wk-old rats (10/group). Dosage: 5-50 mg/kg. Administration: Intraperitoneal injection in 18:00 every day. Result: Plasma glucose was decreased significantly by 27.3%, 34.5% and 61.5%, respectively. Animal Model: Male C57BL/6 J mice, weighing 22-26 g (10 weeks old; PSL mice). Dosage: 25, 50, or 100 mg/kg. Administration: IP 1 h before assessment of thermal hyperalgesia and mechanical allodynia. Result: Remarkably prolonged thermal latency (surgery×treatment interaction, F 1,24 =15.7, p<0.001; surgery×treatment×hours interaction, F 5,120 =3.0, p<0.05) and increased mechanical threshold (surgery×treatment interaction, F 1,24 =18.4, p<0.001; surgery× treatment×hours interaction, F 5,120 =2.6, p<0.05) for 4 h after administration of piromelatine to PSL mice.
IC50& Target:MT 1 MT 2 5-HT 1A Receptor 5-HT 1D Receptor 5-HT 2B Receptor
| ALogP | 1.7 |
|---|
| Isomere SMILES | COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3 |
|---|---|
| Alternative CAS-Nummer | 946846-83-9 |
| PubChem CID | 24815904 |
| MeSH-Eintrag | N-(2-(5-methoxy-indol-3-yl)-ethyl)-4-oxo-4H-pyran-2-carboxamide;Neu-P11;piromelatine |
| Molekulargewicht | 312.32 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →